TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects With at Least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose and dose limited toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal stress change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Infant weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of State-Trait Anxiety Inventory (STAI-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative Pain at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain at 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain at 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain at 96 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cone Beam Computed Tomography (CBCT) Healing Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Tooth Healing Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in daily PM PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to reach the response threshold in IgG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportional IgG Response to serotypes within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: WOMAC (Likert version 3.1)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lequesne index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urinary Excretion of Hydroxylated PAHs (PAH-OHs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who did not resume antiretroviral treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of visible vessels in ulcer base
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Score Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Inferior Corneal Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SNOT 22 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants Who Achieve Body Weight Reduction ≥5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AZD2927
Endpoint domain: Adverse events/effects
Primary endpoint: ACP communication occurrence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: ACP communication quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: absence of immediate allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Cough reflex parameters (C2 and C5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average scores on modified Leicester Cough Questionnaire (LCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of Urticaria/Erythema Score (Physician Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Physician Pruritus Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient Pruritis Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite Acute Urticaria Score Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plaque removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Prevention of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Rate of Canine Retraction in mm Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of observed adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With hSBA-MenC Titer Equal to or Above 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With hSBA-MenY Titer Equal to or Above 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trail Making Part B performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Validity of TIB olfactory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of TIB olfactory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of [14C] radioactivity in plasma and whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma [14C] AZD5069:AZD5069 (cold) ratios for concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount and percentage of radioactive dose recovered in urine, faeces, and renal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Subjects With Major Ipsilateral Stroke/SAH or Death Due to Neurologic Cause
Endpoint domain: Mortality/survival
Primary endpoint: recurrence of urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete cessation of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women achieving vaginal delivery within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall severity of the clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in work ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of subjects reporting prompted local reactions within 14 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects reporting prompted systemic events within 14 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects reporting serious adverse events (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: GDM Outcome Score (GOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2D and obesity at the end of Phase B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of T2D and obesity during Phase C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to attain maximum observed plasma concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multifocal Electroretinography N1-P1 Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Microperimetry Mean Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics levels of haloperidol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry Mouth Questionnaire (DMQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bimanual Ability Test (BAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Immediate complications of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline QUALITY OF LIFE after 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Result of myocardial perfusion SPECT for angina, ischemia or perfusion defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Blood Glucose Concentration After First Day of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CA19-9 levels in urine and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: End-Tidal Carbon Monoxide Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic reduction in 44h-interdialytic ambulatory BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Response with Avelumab in Laryngotracheal RPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response with Avelumab in Pulmonary RPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weight difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PCO rate
Endpoint domain: Mortality/survival
Primary endpoint: Glasgow Prognostic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of cerebral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Surface Microhardness Recovery (% SMHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of Positron Lymphography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLT3 Mutation Negative Composite Complete Response (CRc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the PriMUS clinical decision aid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Respond to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Central Nervous System (CNS) Composite Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hair Clearance 1 Month After Last Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of everolimus
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Time Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant atopic dermatitis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extravasation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in 0-24 Hour Weighted Mean Serum Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Hemoglobin Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NoL index responses to electrical stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live birth rate (LBR)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative live birth rate (CLBR) per couple
Endpoint domain: Mortality/survival
Primary endpoint: Abortion rate (AR)
Endpoint domain: Mortality/survival
Primary endpoint: Pain Freedom (PF) at 2 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Relief (PR) at 2 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell transplantation related side effect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Were Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of TGF-β1 content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in volume transfer coefficient (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical examination of the stomatognathic system (structural)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical examination of the stomatognathic system (functional)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive body posture assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Patency at Three Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative prevalence of chronic respiratory diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Attention Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom of relapse
Endpoint domain: Mortality/survival
Primary endpoint: Development of fever or symptoms of severe malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evidence of malaria infection based on placental histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of molecular markers of sulphadoxine-pyrimethamine resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody level against H1N1 influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in percent root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-management abilities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Orthodontic pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Perceived Exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change of the Body Part Discomfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with immune-mediated hepatitis
Endpoint domain: Adverse events/effects
Primary endpoint: mesenteric lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Percentage of in-stent neointimal tissue formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Palbociclib-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of biventricular stimulated heart cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time of family planning use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in quadriceps muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Fat Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short-term postoperative results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term results after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Hematological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent change from baseline in total thrombus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with various gradations of decrease in total thrombus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with major or clinically relevant nonmajor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of test-retest measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass correlation (ICC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cerebral regional oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mitochondrial density in muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Perihematoma Edema (aPHE) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in 12-lead ECG recordings from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Blood Pressure from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of folate receptor in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improved chewing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of Homocysteine blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expression of CD133 in tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of definite IS cases
Endpoint domain: Adverse events/effects
Primary endpoint: Time to normalization of the platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DKA
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in M30 and M65 Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of proliferation of organoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number screened per week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of those eligible who enroll to the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical Tumor Regression (Complete Response + Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of retinal break
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction of nipple pain during breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Enhanced Lymphedema Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of alarm symptoms for functional constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Predictive value of warning symptoms to malignant intestinal tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical benefit from arzoxifene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased olfactory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neonatal temperature in the normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Plasma Analyte Concentration (Ctrough) of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Analyte Concentration (Cmax) of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[24h]) of JNJ-53718678
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait spatiotemporal variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who experience an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Ineligibility for further cerebral SRS
Endpoint domain: Adverse events/effects